Pulmonx Picks Up $86M IPO Plans After COVID-19 Disruption
Executive Summary
The company originally filed to list on the NASDAQ in February but withdrew as the pandemic hit.
You may also be interested in...
Pulmonx's FDA Nod: First To US Market With Endobronchial Valve System
Pulmonx announced US FDA approval of its Zephyr endobronchial valve system for treating severe emphysema patients. This makes it the first minimally invasive device to be approved in the US for treating severe emphysema, a severe form of chronic obstructive pulmonary disease.
Qiagen’s Ambitions: Standing Alone And Strengthening Infectious Disease Portfolio
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.
Angle Files De Novo Submission For Parsortix System In Breast Cancer
The system has the potential to be the first FDA-cleared device for harvesting intact cancer cells from a blood sample for subsequent analysis.